Navigation Links
PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
Date:4/27/2009

- Consolidated service revenue of $264.5 million grows 7.8% year-over-year

- Operating margin of 10.0%

- Diluted earnings per share of $0.25

- Net quarterly book-to-bill ratio equates to 1.25

BOSTON, April 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter ended March 31, 2009.

For the three months ended March 31, 2009, PAREXEL's consolidated service revenue increased 7.8% to $264.5 million, compared with $245.3 million in the prior year period. Foreign exchange negatively impacted the quarter by $35.7 million dollars. Excluding the negative impact of foreign exchange and the net positive impact of acquisitions and divestitures of $17.0 million from the third quarter of Fiscal Year 2009, and $0.9 million in divestitures from the third quarter of Fiscal Year 2008, revenue grew 15.8% year-over-year. The Company reported operating income of $26.4 million, or 10.0% of consolidated service revenue, in the third quarter of Fiscal Year 2009, versus operating income of $22.7 million, or 9.3% of consolidated service revenue, in the comparable quarter of the prior year. This represented a year-over-year increase of 16.3%. Net income for the quarter totaled $14.2 million, or $0.25 per diluted share, compared with net income of $14.2 million, or $0.25 per diluted share for the quarter ended March 31, 2008.

On a segment basis, consolidated service revenue for the third quarter of Fiscal Year 2009 consisted of $199.7 million in Clinical Research Services (CRS), $29.2 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $35.6 million in Perceptive Informatics, Inc.

For the nine months ended March 31, 2009, PAREXEL's consolidated service revenu
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. PAREXEL Receives BioSingapore Award for Best Performing CRO
2. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
3. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
4. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
5. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
6. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference
7. PAREXEL Receives Best CRO Award from Scrip
8. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
9. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
(Date:7/30/2014)... Yuma, AZ (PRWEB) July 30, 2014 ... , State-of-the-art facility and complementary therapies brings comprehensive ... square foot, state-of-the-art Yuma Regional Cancer Center has ... since 2012, the program includes services such as ... laboratory, massage therapy, American Cancer Society Resource Center, ...
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
Breaking Biology Technology:Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... (Nasdaq: BNVI ) today announced financial ... "Scientific development, regulatory progress and growth accurately characterize ... chairman and chief executive officer. "We successfully laid ... is essential for the successful approval and marketing ...
... Corporation (NYSE: SGP ) is scheduled to ... first quarter on Tuesday, April 21, 2009. At ... a conference call to review results for the 2009 ... and other members of management will host the conference ...
... LLC, and Burrill & Company Collaborating on Strategic ... 12 Developer Tower Investments, LLC ("Tower"), and ... ("Burrill") today announced a formal partnership with aims ... planned development and funding related to the "shovel-ready" ...
Cached Biology Technology:Bionovo Announces 2008 Highlights and Year-End Financial Results 2Bionovo Announces 2008 Highlights and Year-End Financial Results 3Bionovo Announces 2008 Highlights and Year-End Financial Results 4Bionovo Announces 2008 Highlights and Year-End Financial Results 5Bionovo Announces 2008 Highlights and Year-End Financial Results 6Bionovo Announces 2008 Highlights and Year-End Financial Results 7Bionovo Announces 2008 Highlights and Year-End Financial Results 8Bionovo Announces 2008 Highlights and Year-End Financial Results 9Bionovo Announces 2008 Highlights and Year-End Financial Results 10Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... 3,000 pieces is still in its infant stage. But ... of major significance. "Amazingly often, we are findingin addition ... that we found in Baltic amber," explained Bonn paleontologist ... comes from the Baltic Sea region, which is almost ... e.g., the coastal regions of Mecklenburg, Poland and Belarus. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... stress a typical married couple feels during an ordinary half-hour ... from wounds by at least one day, a new study ... routinely hostile toward each other, the delay in that healing ... have major financial implications for medical centers and health care ...
... an AIDS vaccine, UCLA AIDS Institute researchers report the ... the infection in different ways. , Detailed in the ... ( http://jvi.asm.org ), the findings show that the body's ... determined. , The researchers followed the cases of male ...
... much more sophisticated visual system than previously thought, according ... which bees were able to solve complicated colour puzzles. ... of the most difficult challenges of vision - namely, ... by suggesting that bees solve this problem using their ...
Cached Biology News:Stress substantially slows human body's ability to heal 2Stress substantially slows human body's ability to heal 3UCLA scientists discover immune response to HIV differs, even in identical twins 2Bees solve complex colour puzzles 2
Rabbit Serum New Zealand or California Origin...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
... , Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... will be returned to customer conjugation of peptide to KLH protein ... Maintenance 102 days/each , Pre-immune bleed x1 ... , Test bleed (app. 5 ml) x1 /each ...
... collected off the clot fasted non-Swiss Albino mice of ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
Biology Products: